Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31452810 | 1.00 | CYP2D6 (0.56) | CYP2D6KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL9903935 | 0.89 | CYP2D6 (0.60) | CYP2D6MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL8499115 | 0.81 | CYP2D6 (0.53) | CYP2D6NPC1RAB9AMAPK9MAPT | |
| SCHEMBL27663024 | 0.81 | CYP2D6 (0.46) | CYP2D6NPC1RAB9AGAAMAP4K4 | |
| SCHEMBL1061567 | 0.78 | CYP2D6 (0.51) | CYP2D6MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL15651713 | 0.78 | CYP2D6 (0.51) | CYP2D6KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL17690417 | 0.78 | CYP2D6 (0.51) | CYP2D6MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL675705 | 0.78 | CYP2D6 (0.51) | CYP2D6MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL3157652 | 0.78 | NOTUM (0.52) | CYP2D6MAPK9MAPTNOTUMMAPK14 | |
| SCHEMBL8566727 | 0.78 | CYP2D6 (0.51) | CYP2D6KMT2AKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | claimed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | claimed |
| WO-2021120838-A1 | ORGANIC COMPOUND, ELECTRONIC DEVICE, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-108137565-A | Heterocyclic compound, light-emitting element, light-emitting device, electronic device, and lighting device | 株式会社半导体能源研究所 | 2018-06-08 | — | — | CN | disclosed |
| CN-105153026-B | Sorafenib derivative of the amide structure containing biaryl and its preparation method and application | 江西科技师范大学 | 2018-02-02 | — | — | CN | disclosed |
| CN-107108615-A | Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds | 吉利德科学公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-103456899-B | Organic material, light-emitting component, light-emitting device, electronic equipment and illuminator | 株式会社半导体能源研究所 | 2017-03-01 | — | — | CN | disclosed |
| CN-106083936-A | Organometallic complex, light-emitting component, light-emitting device, electronic equipment and illuminator | 株式会社半导体能源研究所 | 2016-11-09 | — | — | CN | disclosed |
| CN-104170111-B | Light-emitting element, light-emitting device, display device, electronic device, and lighting device | 株式会社半导体能源研究所 | 2016-10-26 | — | — | CN | disclosed |
| CN-103168043-B | Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device | 株式会社半导体能源研究所 | 2016-08-03 | — | — | CN | disclosed |
| CN-105732588-A | Organic Compound, Light-Emitting Element, Display Module, Lighting Module, Light-Emitting Device, Display Device, Electronic Device, and Lighting Device | 株式会社半导体能源研究所 | 2016-07-06 | — | — | CN | disclosed |
| WO-2011132051-A2 | TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | UNIVERSITY OF OTTAWA | 2008-06-05 | — | — | US | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | CYP2D6 112/4885KMT2A 3345/4885KDM4E 2584/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | CYP2D6 199/4885KMT2A 673/4885KDM4E 2/4885 |
| US-20080132698-A1 | Use of N-oxide compounds in coupling reactions | CYP4X1, CYP4F3, CYP1A2 | CYP2D6 102/4885KMT2A 3236/4885KDM4E 3999/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | CYP2D6 234/4885KMT2A 657/4885KDM4E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.